MY188379A - Crystalline form of compound suppressing protein kinase activity, and application thereof - Google Patents

Crystalline form of compound suppressing protein kinase activity, and application thereof

Info

Publication number
MY188379A
MY188379A MYPI2018002245A MYPI2018002245A MY188379A MY 188379 A MY188379 A MY 188379A MY PI2018002245 A MYPI2018002245 A MY PI2018002245A MY PI2018002245 A MYPI2018002245 A MY PI2018002245A MY 188379 A MY188379 A MY 188379A
Authority
MY
Malaysia
Prior art keywords
crystalline form
compound
application
protein kinase
kinase activity
Prior art date
Application number
MYPI2018002245A
Other languages
English (en)
Inventor
Congxin Liang
Yongbin Ma
Wei He
Original Assignee
Xcovery Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcovery Holdings Inc filed Critical Xcovery Holdings Inc
Publication of MY188379A publication Critical patent/MY188379A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MYPI2018002245A 2016-06-01 2017-06-01 Crystalline form of compound suppressing protein kinase activity, and application thereof MY188379A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/084300 2016-06-01
PCT/CN2017/086760 WO2017206924A1 (zh) 2016-06-01 2017-06-01 抑制蛋白激酶活性化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
MY188379A true MY188379A (en) 2021-12-07

Family

ID=60477983

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018002245A MY188379A (en) 2016-06-01 2017-06-01 Crystalline form of compound suppressing protein kinase activity, and application thereof

Country Status (17)

Country Link
US (1) US10899744B2 (cg-RX-API-DMAC7.html)
EP (1) EP3470410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7054528B2 (cg-RX-API-DMAC7.html)
KR (1) KR102466958B1 (cg-RX-API-DMAC7.html)
CN (1) CN109195964B (cg-RX-API-DMAC7.html)
AU (1) AU2017274110B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026142C (cg-RX-API-DMAC7.html)
EA (1) EA201892687A1 (cg-RX-API-DMAC7.html)
ES (1) ES2981015T3 (cg-RX-API-DMAC7.html)
IL (1) IL263356B (cg-RX-API-DMAC7.html)
MY (1) MY188379A (cg-RX-API-DMAC7.html)
PH (1) PH12018502529A1 (cg-RX-API-DMAC7.html)
PL (1) PL3470410T3 (cg-RX-API-DMAC7.html)
RU (1) RU2744264C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201810800VA (cg-RX-API-DMAC7.html)
TW (1) TWI646094B (cg-RX-API-DMAC7.html)
WO (1) WO2017206924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279579B2 (en) 2018-06-21 2023-02-01 Betta Pharmaceuticals Co Ltd Crystalline form of a compound to inhibit the activity of cdk4/6 and its use
WO2022031636A1 (en) 2020-08-03 2022-02-10 Teva Pharmaceuticals International Gmbh Solid state forms of ensartinib and ensartinib salts
CN117897156A (zh) * 2021-08-10 2024-04-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
KR102851417B1 (ko) * 2022-08-16 2025-08-28 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제
CN118021811A (zh) * 2023-12-28 2024-05-14 复旦大学附属华山医院 一种靶向于csf1r激酶的6-氟吡啶甲酰苯胺类抑制剂、药物组合物及其核素成像试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1963302E (pt) 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
CN101652068A (zh) * 2007-01-19 2010-02-17 艾科睿制药公司 激酶抑制物化合物
KR101691640B1 (ko) * 2008-06-19 2016-12-30 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
EA025030B1 (ru) * 2010-10-08 2016-11-30 Икскавери Холдинг Кампани, Ллс Соединение {5-[(1r)-1-(2,6-дихлор-3-фторфенил)этокси]-6-аминопиридазин-3-ил}-n-(1-метил-6-оксо-1,6-дигидропиридин-3-ил)карбоксамид в качестве киназного ингибитора
EP2625176B1 (en) * 2010-10-08 2016-08-17 Xcovery Holding Company LLC Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Also Published As

Publication number Publication date
KR20190012231A (ko) 2019-02-08
WO2017206924A1 (zh) 2017-12-07
US20190135792A1 (en) 2019-05-09
HK1259249A1 (zh) 2019-11-29
EA201892687A1 (ru) 2019-06-28
TWI646094B (zh) 2019-01-01
SG11201810800VA (en) 2019-01-30
RU2744264C2 (ru) 2021-03-04
AU2017274110A1 (en) 2019-01-24
US10899744B2 (en) 2021-01-26
PL3470410T3 (pl) 2024-09-16
JP2019518026A (ja) 2019-06-27
ES2981015T3 (es) 2024-10-04
AU2017274110B2 (en) 2021-05-06
NZ788961A (en) 2024-12-20
NZ750921A (en) 2024-12-20
IL263356B (en) 2022-08-01
CA3026142A1 (en) 2017-12-07
RU2018145183A3 (cg-RX-API-DMAC7.html) 2020-07-16
EP3470410A4 (en) 2019-12-04
TW201742865A (zh) 2017-12-16
CN109195964B (zh) 2021-08-10
EP3470410B1 (en) 2024-04-17
RU2018145183A (ru) 2020-07-14
PH12018502529A1 (en) 2019-04-08
EP3470410A1 (en) 2019-04-17
CN109195964A (zh) 2019-01-11
IL263356A (en) 2018-12-31
CA3026142C (en) 2024-02-13
BR112018074612A2 (pt) 2019-03-19
JP7054528B2 (ja) 2022-04-14
KR102466958B1 (ko) 2022-11-14

Similar Documents

Publication Publication Date Title
PH12018502529A1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12020500125A1 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2015018032A (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
SA518391518B1 (ar) مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
IN2014KN00948A (cg-RX-API-DMAC7.html)
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
MY202126A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
MY197494A (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
MX379558B (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida.
MX2015012111A (es) Moduladores de ship1 y métodos relacionados con éstos.
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP4349330A3 (en) Method of treating conditions related to the pgi2 receptor
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
MX387639B (es) Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.
MX392359B (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas
MX2020005646A (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico.
MX2024000903A (es) Formas cristalinas.
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona